Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

May 30, 2024

https://www.globenewswire.com/news-release/2024/05/30/2890753/0/en/Ascendis-to-Spotlight-Latest-Updates-for-TransCon-Rare-Endocrinology-Disease-Portfolio-at-ENDO-2024.html

COPENHAGEN, Denmark, May 30, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:ASND) today announced that it will host informational booths, events, and presentations showcasing use of its innovative TransCon technology in the areas of growth hormone deficiency (GHD), hypoparathyroidism, achondroplasia, and Turner syndrome during ENDO 2024, the annual meeting of the Endocrine Society being held June 1-4, 2024, in Boston.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.